𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I clinical evaluation of a new iron oxide MR contrast agent

✍ Scribed by Stuart J. McLachlan; Marie R. Morris; Maria A. Lucas; Ricardo A. Fisco; Michael N. Eakins; Dennis R. Fowler; R. Bradley Scheetz; Adeoye Y. Olukotun

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
735 KB
Volume
4
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The safety and magnetic resonance (MR) imaging potential of BMS 180549, a new superparamagnetic iron oxide contrast agent, were evaluated in a phase I, open‐label, placebo‐controlled study involving 41 healthy subjects. No clinically significant postdose changes in physical examination findings, vital signs, or electrocardiogram results were reported for any of the subjects evaluated. No clinically significant changes in clinical laboratory values were noted by the investigators. Fourteen adverse events considered not serious and considered possibly or definitely related to the drug were reported, three of which required minor treatment. Relaxation time measurements in plasma samples showed a strong, dose‐dependent, and persistent decrease in T1 and T2 values. Significant changes in MR signal intensity of the blood pool and wellperfused organs (liver and spleen) were noted on both T1‐ and T2‐weighted images. Changes in signal intensity of cervical lymph nodes were also observed at the higher doses and late postdose imaging times.

📜 SIMILAR VOLUMES

Preliminary evaluation of iron phytate (
Preliminary evaluation of iron phytate (inositol hexaphosphate) as a gastrointestinal MR contrast agent
✍ Evan C. Unger; Thomas A. Fritz; David Palestrant; Thomas J. Meakem; Per Granstro 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

## Abstract A simple, effective, safe, and well‐tolerated contrast agent is needed as a bowel marker for magnetic resonance (MR) imaging. The authors tested a variety of foodstuffs admixed with ferric iron as potential gastrointestinal MR contrast agents. Phytate (inosi‐tol hexaphosphate) more than

Safety and efficacy of a novel hepatobil
Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: Results of phase I and phase II clinical trials
✍ Akihiro Tanimoto; Masumi Kadoya; Yasutaka Kawamura; Ryohei Kuwatsuru; Takehiko G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

## Abstract ## Purpose To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd‐DTPA‐DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. ## Materials and Methods In a phase I trial, 33 healthy volunteers were intravenously

Preliminary clinical trial of gadodiamid
Preliminary clinical trial of gadodiamide injection: A new nonionic gadolinium contrast agent for MR imaging
✍ Gabriela D. Kaplan; Alex M. Aisen; S. Rao Aravapalli 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 685 KB

The safety and efficacy of a newly developed intravenous formulation of the nonionic contrast agent gadolinium diethylenetriaminepentaacetic acid-bis(methylamide), formulated as gadodiamide injection, was investigated. In 30 patients who underwent spin-echo magnetic resonance (MR) imaging before and

Long-term imaging effects in rat liver a
Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent
✍ Karen Briley-Sæbø; Svein-Olaf Hustvedt; Anita Haldorsen; Atle Bjørnerud 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB

## Abstract ## Purpose To investigate the duration of liver R2\* enhancement and pharmacokinetics following administration of an iron oxide nanoparticle in a rat model. ## Materials and Methods Rats were injected with 0, 1, 2, or 5 mg Fe/kg of NC100150 Injection, and quantitative in vivo 1/T2\*

Evaluation of a new ultrasmall superpara
Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan®, (NC100150) for MRI of renal perfusion: Experimental study in an animal model
✍ Rainald Bachmann; Rudolf Conrad; Burkhard Kreft; Oliver Luzar; Wolfgang Block; S 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 544 KB

## Abstract ## Purpose To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan®, (NC100150) for the evaluation of renal perfusion in an animal model using a 3D‐FFE‐EPI sequence. ## Materials and Methods Four groups of four rabbits each were imaged after bolus